Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Decreases By 38.1%

Posted by Chris Copeland on Jan 31st, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the target of a large decline in short interest in January. As of January 15th, there was short interest totaling 7,035 shares, a decline of 38.1% from the December 31st total of 11,368 shares. Based on an average daily trading volume, of 19,600 shares, the short-interest ratio is presently 0.4 days. Based on an average daily trading volume, of 19,600 shares, the short-interest ratio is presently 0.4 days.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned approximately 0.30% of Pulmatrix as of its most recent SEC filing. 11.84% of the stock is owned by hedge funds and other institutional investors.

Pulmatrix Price Performance

Shares of NASDAQ PULM traded down $0.05 during midday trading on Friday, hitting $2.57. 6,450 shares of the stock traded hands, compared to its average volume of 14,806. Pulmatrix has a one year low of $2.15 and a one year high of $10.40. The firm has a 50-day moving average of $3.13 and a two-hundred day moving average of $4.35.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix currently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on PULM

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).